Capital Analysts LLC Sells 39 Shares of Eli Lilly and Company (NYSE:LLY)

Capital Analysts LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,084 shares of the company’s stock after selling 39 shares during the quarter. Capital Analysts LLC’s holdings in Eli Lilly and Company were worth $632,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in LLY. Private Client Services LLC acquired a new stake in Eli Lilly and Company in the 4th quarter valued at $543,000. Keel Point LLC boosted its holdings in shares of Eli Lilly and Company by 2.4% in the 4th quarter. Keel Point LLC now owns 2,060 shares of the company’s stock worth $1,201,000 after buying an additional 49 shares during the last quarter. Aurora Private Wealth Inc. boosted its holdings in shares of Eli Lilly and Company by 26.5% in the 4th quarter. Aurora Private Wealth Inc. now owns 1,130 shares of the company’s stock worth $659,000 after buying an additional 237 shares during the last quarter. Sippican Capital Advisors boosted its holdings in shares of Eli Lilly and Company by 21.9% in the 4th quarter. Sippican Capital Advisors now owns 4,677 shares of the company’s stock worth $2,726,000 after buying an additional 841 shares during the last quarter. Finally, Bison Wealth LLC boosted its holdings in shares of Eli Lilly and Company by 11.2% in the 4th quarter. Bison Wealth LLC now owns 5,008 shares of the company’s stock worth $2,919,000 after buying an additional 504 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on LLY. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Bank of America boosted their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. Finally, Truist Financial restated a “buy” rating and issued a $850.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Stock Down 0.6 %

Shares of NYSE LLY opened at $746.56 on Wednesday. Eli Lilly and Company has a 12 month low of $367.35 and a 12 month high of $800.78. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The firm has a market capitalization of $709.35 billion, a price-to-earnings ratio of 128.72, a PEG ratio of 1.64 and a beta of 0.34. The business has a 50-day moving average of $763.51 and a 200-day moving average of $657.01.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.09 earnings per share. Sell-side analysts expect that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the sale, the insider now owns 99,488,598 shares of the company’s stock, valued at $64,177,109,911.86. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.13% of the stock is owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.